{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:20:21Z","timestamp":1782260421257,"version":"3.54.5"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hydroxyurea has long been used for the treatment of sickle cell anemia (SCA), and its clinical effectiveness is related to the induction of fetal hemoglobin (HbF), a major modifier of SCA phenotypes. However, there is substantial variability in response to hydroxyurea among patients with SCA. While some patients show an increase in HbF levels and an ameliorated clinical condition under low doses of hydroxyurea, other patients present a poor effect or even develop toxicity. However, the effects of genetic polymorphisms on increasing HbF levels in response to hydroxyurea in patients with SCA (Hb SS) have been less explored. Therefore, we performed a systematic review to assess whether single-nucleotide polymorphisms (SNPs) affect HbF levels in patients with SCA treated with hydroxyurea. Moreover, we performed pathway analysis using the set of genes with SNPs found to be associated with changes in HbF levels in response to hydroxyurea among the included studies. The systematic literature search was conducted on Medline\/PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Web of Science. Seven cohort studies were included following our inclusion and exclusion criteria. From the 728 genetic polymorphisms examined in the included studies, 50 different SNPs of 17 genes were found to be associated with HbF changes in patients with SCA treated with hydroxyurea, which are known to affect baseline HbF but are not restricted to them. Enrichment analysis of this gene set revealed reactome pathways with the lowest adjusted <jats:italic>p<\/jats:italic>-values and highest combined scores related to VEGF ligand\u2013receptor interactions (R-HSA-194313; R-HSA-195399) and the urea cycle (R-HSA-70635). Pharmacogenetic studies of response to hydroxyurea therapy in patients with SCA are still scarce and markedly heterogeneous regarding candidate genes and SNPs examined for association with HbF changes and outcomes, suggesting that further studies are needed. The reviewed findings highlighted that similar to baseline HbF, changes in HbF levels upon hydroxyurea therapy are likely to be regulated by multiple loci. There is evidence that SNPs in intron 2 of <jats:italic>BCL11A<\/jats:italic> affect HbF changes in response to hydroxyurea therapy, a potential application that might improve the clinical management of SCA.<\/jats:p><jats:p><jats:bold>Systematic Review Registration: <\/jats:bold>(<jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=208790<\/jats:ext-link>).<\/jats:p>","DOI":"10.3389\/fphar.2021.779497","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:39:06Z","timestamp":1642754346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Do Genetic Polymorphisms Affect Fetal Hemoglobin (HbF) Levels in Patients With Sickle Cell Anemia Treated With Hydroxyurea? A Systematic Review and Pathway Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Rahyssa Rodrigues","family":"Sales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Lisboa","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica Abdo Gon\u00e7alves","family":"Tosatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Braga","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Rizzatti","family":"Luizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1002\/ajh.24680","article-title":"Genetic Modulation of Fetal Hemoglobin in Hydroxyurea-Treated Sickle Cell Anemia","volume":"92","author":"Aleluia","year":"2017","journal-title":"Am. J. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.mcna.2016.09.009","article-title":"Sickle Cell Disease: A Brief Update","volume":"101","author":"Azar","year":"2017","journal-title":"Med. Clin. North. Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2217\/pgs.12.125","article-title":"KLF10 Gene Expression Is Associated with High Fetal Hemoglobin Levels and with Response to Hydroxyurea Treatment in \u03b2-hemoglobinopathy Patients","volume":"13","author":"Borg","year":"2012","journal-title":"Pharmacogenomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40246-017-0120-8","article-title":"Whole Transcriptome Analysis of Human Erythropoietic Cells during Ontogenesis Suggests a Role of VEGFA Gene as Modulator of Fetal Hemoglobin and Pharmacogenomic Biomarker of Treatment Response to Hydroxyurea in \u03b2-type Hemoglobinopathy Patients","volume":"11","author":"Chondrou","year":"2017","journal-title":"Hum. Genomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Prevention, Diagnosis, and Treatment of Cerebrovascular Disease in Children and Adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<7:AID-HUMU4>3.0.CO;2-N","article-title":"Mutation Nomenclature Extensions and Suggestions to Describe Complex Mutations: a Discussion","volume":"15","author":"den Dunnen","year":"2000","journal-title":"Hum. Mutat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/MPH.0000000000000762","article-title":"Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients with Hemoglobinopathies","volume":"39","author":"Elalfy","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/01.RES.0000082524.34487.31","article-title":"Regulation of Nitric Oxide-Sensitive Guanylyl Cyclase","volume":"93","author":"Friebe","year":"2003","journal-title":"Circ. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bcmd.2016.11.002","article-title":"The Role of BCL11A and HMIP-2 Polymorphisms on Endogenous and Hydroxyurea Induced Levels of Fetal Hemoglobin in Sickle Cell Anemia Patients from Southern Brazil","volume":"62","author":"Friedrisch","year":"2016","journal-title":"Blood Cell Mol. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ng.707","article-title":"Fine-mapping at Three Loci Known to Affect Fetal Hemoglobin Levels Explains Additional Genetic Variation","volume":"42","author":"Galarneau","year":"2010","journal-title":"Nat. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1002\/cpz1.226","article-title":"PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge","volume":"1","author":"Gong","year":"2021","journal-title":"Curr. Protoc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2217\/pgs-2016-0076","article-title":"Correlation of SIN3A Genomic Variants with \u03b2-hemoglobinopathies Disease Severity and Hydroxyurea Treatment Efficacy","volume":"17","author":"Gravia","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e55709","DOI":"10.1371\/journal.pone.0055709","article-title":"Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea","volume":"8","author":"Green","year":"2013","journal-title":"PLoS One"},{"key":"B16","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","author":"Higgins","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinbiochem.2010.08.006","article-title":"The Effect of UGT1A1 Promoter Polymorphism on Bilirubin Response to Hydroxyurea Therapy in Hemoglobinopathies","volume":"43","author":"Italia","year":"2010","journal-title":"Clin. Biochem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"D498","DOI":"10.1093\/nar\/gkz1031","article-title":"The Reactome Pathway Knowledgebase","volume":"48","author":"Jassal","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle Cell Disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood.2020005058","article-title":"Understanding Heterogeneity of Fetal Hemoglobin Induction through Comparative Analysis of F and A Erythroblasts","volume":"135","author":"Khandros","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.freeradbiomed.2004.02.073","article-title":"Nitric Oxide Production from Hydroxyurea","volume":"37","author":"King","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2141.2008.07045.x","article-title":"Fetal Haemoglobin Response to Hydroxycarbamide Treatment and Sar1a Promoter Polymorphisms in Sickle Cell Anaemia","volume":"141","author":"Kumkhaek","year":"2008","journal-title":"Br. J. Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10133","DOI":"10.1038\/s41598-020-66309-x","article-title":"Comparative Targeting Analysis of KLF1, BCL11A, and HBG1\/2 in CD34+ HSPCs by CRISPR\/Cas9 for the Induction of Fetal Hemoglobin","volume":"10","author":"Lamsfus-Calle","year":"2020","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","article-title":"Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments","volume":"20","author":"Lauschke","year":"2017","journal-title":"AAPS J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/S0140-6736(15)01341-0","article-title":"Fetal Haemoglobin in Sickle-Cell Disease: from Genetic Epidemiology to New Therapeutic Strategies","volume":"387","author":"Lettre","year":"2016","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.1073\/pnas.0804799105","article-title":"DNA Polymorphisms at the BCL11A, HBS1L-MYB, and Beta-Globin Loci Associate with Fetal Hemoglobin Levels and Pain Crises in Sickle Cell Disease","volume":"105","author":"Lettre","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2217\/pgs.15.121","article-title":"Uncovering Drug-Responsive Regulatory Elements","volume":"16","author":"Luizon","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/sj.tpj.6500433","article-title":"Fetal Hemoglobin in Sickle Cell Anemia: Genetic Determinants of Response to Hydroxyurea","volume":"7","author":"Ma","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5551\/jat.13.130","article-title":"Signal Transduction via Vascular Endothelial Growth Factor (VEGF) Receptors and Their Roles in Atherogenesis","volume":"13","author":"Matsumoto","year":"2006","journal-title":"J. Atheroscler. Thromb."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea Therapy for Sickle Cell Anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fgene.2019.00509","article-title":"Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa","volume":"10","author":"Mnika","year":"2019","journal-title":"Front. Genet."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-20-08","article-title":"Chapter 7: Systematic Reviews of Etiology and Risk","volume-title":"JBI Manual for Evidence Synthesis","author":"Moola","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1616S","DOI":"10.1093\/jn\/137.6.1616S","article-title":"Regulation of Nitric Oxide Synthesis and Apoptosis by Arginase and Arginine Recycling","volume":"137","author":"Mori","year":"2007","journal-title":"J. Nutr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.niox.2018.10.003","article-title":"Hydroxyurea Therapy Modulates Sickle Cell Anemia Red Blood Cell Physiology: Impact on RBC Deformability, Oxidative Stress, Nitrite Levels and Nitric Oxide Synthase Signalling Pathway","volume":"81","author":"Nader","year":"2018","journal-title":"Nitric Oxide"},{"key":"B36","article-title":"Evidence-Based Management of Sickle Cell Disease: Expert Panel Report","year":"2014"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.chest.2015.12.016","article-title":"Crises in Sickle Cell Disease","volume":"149","author":"Novelli","year":"2016","journal-title":"Chest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","article-title":"A Systematic Review of Known Mechanisms of Hydroxyurea-Induced Fetal Hemoglobin for Treatment of Sickle Cell Disease","volume":"8","author":"Pule","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40169-016-0092-7","article-title":"Hydroxyurea Down-Regulates BCL11A, KLF-1 and MYB through miRNA-Mediated Actions to Induce \u03b3-globin Expression: Implications for New Therapeutic Approaches of Sickle Cell Disease","volume":"5","author":"Pule","year":"2016","journal-title":"Clin. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/s0140-6736(87)91481-4","article-title":"Endogenous Nitric Oxide Inhibits Human Platelet Adhesion to Vascular Endothelium","volume":"2","author":"Radomski","year":"1987","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bcmd.2017.08.017","article-title":"Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia, IReal-Life Experience with Hydroxyurea in Sickle Cell Disease: A Multicenter Study in a Cohort of Patients with Heterogeneous Descent","volume":"69","author":"Rigano","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e100516","DOI":"10.1371\/journal.pone.0100516","article-title":"The Co-inheritance of Alpha-Thalassemia and Sickle Cell Anemia Is Associated with Better Hematological Indices and Lower Consultations Rate in Cameroonian Patients and Could Improve Their Survival","volume":"9","author":"Rumaney","year":"2014","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00277-020-04079-2","article-title":"Functional Polymorphisms of BCL11A and HBS1L-MYB Genes Affect Both Fetal Hemoglobin Level and Clinical Outcomes in a Cohort of Children with Sickle Cell Anemia","volume":"99","author":"Sales","year":"2020","journal-title":"Ann. Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.4081\/hr.2016.6678","article-title":"Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures","volume":"8","author":"Sclafani","year":"2016","journal-title":"Hematol. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e110740","DOI":"10.1371\/journal.pone.0110740","article-title":"Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia","volume":"9","author":"Sheehan","year":"2014","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/17474086.2016.1255142","article-title":"Fetal Hemoglobin Regulation in \u03b2-thalassemia: Heterogeneity, Modifiers and Therapeutic Approaches","volume":"9","author":"Sripichai","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1172\/JCI71520","article-title":"HBS1L-MYB Intergenic Variants Modulate Fetal Hemoglobin via Long-Range MYB Enhancers","volume":"124","author":"Stadhouders","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"Management of Sickle Cell Disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1100\/tsw.2008.157","article-title":"Sickle Cell Anemia, the First Molecular Disease: Overview of Molecular Etiology, Pathophysiology, and Therapeutic Approaches","volume":"8","author":"Steinberg","year":"2008","journal-title":"Sci. World J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of Observational Studies in Epidemiology: a Proposal for Reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1182\/blood-2003-10-3458","article-title":"The Hydroxyurea-Induced Small GTP-Binding Protein SAR Modulates Gamma-Globin Gene Expression in Human Erythroid Cells","volume":"106","author":"Tang","year":"2005","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11346","DOI":"10.1073\/pnas.0611393104","article-title":"Intergenic Variants of HBS1L-MYB Are Responsible for a Major Quantitative Trait Locus on Chromosome 6q23 Influencing Fetal Hemoglobin Levels in Adults","volume":"104","author":"Thein","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Hydroxyurea Treatment for Children with Sickle Cell Anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I Use Hydroxyurea to Treat Young Patients with Sickle Cell Anemia","volume":"115","author":"Ware","year":"2010","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e92506","DOI":"10.1371\/journal.pone.0092506","article-title":"Association of Variants at BCL11A and HBS1L-MYB with Hemoglobin F and Hospitalization Rates Among Sickle Cell Patients in Cameroon","volume":"9","author":"Wonkam","year":"2014","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.freeradbiomed.2008.01.008","article-title":"Sickle Cell Disease Vasculopathy: a State of Nitric Oxide Resistance","volume":"44","author":"Wood","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1182\/blood.V104.11.108.108","article-title":"Genetic Polymorphisms Associated with Fetal Hemoglobin Response to Hydroxyurea in Patients with Sickle Cell Anemia","volume":"104","author":"Wyszynski","year":"2004","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr. Protoc."},{"key":"B60","doi-asserted-by":"publisher","first-page":"553064","DOI":"10.3389\/fphar.2020.553064","article-title":"Sickle Cell Anemia: Variants in the CYP2D6, CAT, and SLC14A1 Genes Are Associated with Improved Hydroxyurea Response","volume":"11","author":"Yahou\u00e9d\u00e9hou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/ng.637","article-title":"KLF1 Regulates BCL11A Expression and Gamma- to Beta-Globin Gene Switching","volume":"42","author":"Zhou","year":"2010","journal-title":"Nat. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3324\/haematol.2017.175646","article-title":"Hydroxyurea Differentially Modulates Activator and Repressors of \u03b3-globin Gene in Erythroblasts of Responsive and Non-responsive Patients with Sickle Cell Disease in Correlation with Index of Hydroxyurea Responsiveness","volume":"102","author":"Zhu","year":"2017","journal-title":"Haematologica"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.779497\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:39:11Z","timestamp":1642754351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.779497\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":62,"alternative-id":["10.3389\/fphar.2021.779497"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.779497","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"779497"}}